Data / Form D filings / Zyversa Therapeutics, Inc.
Zyversa Therapeutics, Inc.: Form D filings
Zyversa Therapeutics, Inc., a pharmaceuticals company in Weston, FL, filed 9 Form D notices with the SEC between 2014 and 2022. The latest, on April 14, 2022, reports $419,320 sold of a $7 million offering to 4 investors.
Find out what Zyversa Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2200 N. COMMERCE PARKWAY, SUITE 208, Weston, FL, 33326
- Phone
- (646) 414-6965
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Florida
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1613083
The full lists. Form D filings in Florida: 2,702 rows, $107.02, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 14, 2022 | New notice | $7,000,000 | $419,320 | $6,580,680 | 4 | Mar 30, 2022 | sec.gov |
| Nov 1, 2019 | New notice | $20,000,000 | $1,277,500 | $18,722,500 | 19 | Oct 22, 2019 | sec.gov |
| Feb 5, 2018 | New notice | $1,651,669 | $1,403,627 | $248,042 | 20 | Jan 19, 2018 | sec.gov |
| Mar 2, 2017 | New notice | $7,000,000 | $525,000 | $6,475,000 | 7 | Jan 6, 2017 | sec.gov |
| Oct 26, 2016 | Amendment | $4,000,000 | $1,505,000 | $2,495,000 | 21 | Mar 11, 2016 | sec.gov |
| Apr 21, 2016 | New notice | $2,000,000 | $0 | $2,000,000 | 0 | Yet to occur | sec.gov |
| Jan 21, 2016 | New notice | $25,000,000 | $0 | $25,000,000 | 0 | Yet to occur | sec.gov |
| Feb 3, 2015 | Amendment | $3,500,000 | $2,980,000 | $520,000 | 17 | Jul 15, 2014 | sec.gov |
| Jul 11, 2014 | New notice | $2,500,000 | $0 | $2,500,000 | 0 | Yet to occur | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Melda Uzbil O'Connell | Executive Officer | |
| Nick LaBella | Executive Officer | |
| Stephen Glover | Executive Officer, Director | |
| Robert G Finizio | Director | |
| Peter Wolfe | Executive Officer | |
| Minchul G Park | Director | |
| Pablo Guzman | Executive Officer | |
| Karen Cashmere | Executive Officer |
Other pharmaceuticals companies in Florida that filed recently
- GOA Therapeutics Corp $300,000 · Nov 5, 2026
- DalCor Pharmaceuticals US, LLC $7 million · Aug 28, 2026
Every Form D from the week of Apr 11, 2022 · All recent filings in Florida · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Zyversa Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.